Kisspeptin-10 vs PT-141 (Bremelanotide)
A powerful reproductive hormone regulator that acts like the master switch for your body's fertility system—triggering the release of hormones that control everything from ovulation to testosterone production.
The first FDA-approved peptide that works through your brain to reignite sexual desire—think of it as flipping the 'on' switch for arousal rather than just boosting blood flow like traditional ED meds.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Kisspeptin-10
100–100 mcg
PT-141 (Bremelanotide)
1.75–1.75 mg
Frequency
Kisspeptin-10
Once daily
PT-141 (Bremelanotide)
As needed
Administration
Kisspeptin-10
Subcutaneous injection
PT-141 (Bremelanotide)
Subcutaneous injection
Cycle length
Kisspeptin-10
4-6 weeks
PT-141 (Bremelanotide)
Ongoing/indefinite
Onset speed
Kisspeptin-10
Rapid (hours to days)
PT-141 (Bremelanotide)
Rapid (hours to days)
Evidence level
Kisspeptin-10
Moderate human trials (Phase 1-2)
PT-141 (Bremelanotide)
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Hormone Activation
Sexual Health
Fertility Support
Sexual Desire
On-Demand Use
Clinical Evidence
Compound specifications
Kisspeptin-10
Molecular formula
C63H83N17O14
Molecular weight
1302.45 g/mol
Half-life
~4 minutes (IV); slightly longer subcutaneously
Bioavailability
High when injected; lower intranasal but still effective
CAS number
374675-21-5
PT-141 (Bremelanotide)
Molecular formula
C50H68N14O10
Molecular weight
1025.2 g/mol
Half-life
2.7 hours
Bioavailability
~100% (subcutaneous injection)
CAS number
189691-06-3
Dosing compared
Kisspeptin-10
Subcutaneous
50 mcg per injection
Once daily · 1-2 weeks
Conservative subcutaneous entry dose used in research practice; kisspeptin-10 has a very short half-life (~4 min IV) so effects are pulse-like [1].
100 mcg per injection
Once daily · 4-6 weeks
Common research/practice subcutaneous dose; roughly approximates the ~1 mcg/kg level shown to maximally stimulate LH in men [6].
100-200 mcg per injection
Once or twice daily · 4-6 weeks
Upper end of the practice range; higher kisspeptin-10 doses can blunt the LH response (a ceiling/desensitization effect was seen above ~1 mcg/kg) so escalating beyond this is not advised [6].
Intravenous
1 mcg/kg bolus
Single bolus (research setting) · Single administration
Peer-reviewed human dose: an IV bolus of 1 mcg/kg produced the greatest LH stimulation in healthy men (rising from ~4 to ~12 IU/L at 30 min); 3 mcg/kg gave a smaller response [6]. Used in clinical research, not for routine self-administration.
PT-141 (Bremelanotide)
Subcutaneous
1 mg
As needed, ~45 min before sexual activity; no more than once per 24 h · Trial period (assess response/tolerability)
Lower 1 mg trial dose used in practice to gauge nausea tolerance before moving to the FDA dose [6]. Inject into abdomen or thigh.
1.75 mg
As needed, ~45 min before sexual activity; max once per 24 h and 8 doses per 28 days · Ongoing as needed
FDA-approved Vyleesi dose for hypoactive sexual desire disorder in premenopausal women; efficacy shown in the RECONNECT phase 3 trials [1][6].
Best suited for
Kisspeptin-10
Fertility and IVF Support
Kisspeptin is showing remarkable promise as a safer alternative to traditional IVF triggers. Unlike hCG, it dramatically reduces the risk of ovarian hyperstimulation syndrome (OHSS)—a potentially dangerous IVF complication. Studies show kisspeptin can mature eggs effectively while keeping ovarian volume 3x smaller than with hCG [3][13].
Natural Testosterone Optimization in Men
Rather than replacing your testosterone from outside (which shuts down natural production), kisspeptin tells your brain to make more. It stimulates LH release, which signals your testes to produce testosterone naturally. [6][7] This approach maintains fertility and testicular function—unlike exogenous testosterone [22].
Low Sexual Desire (Hypoactive Sexual Desire Disorder)
Clinical trials have shown kisspeptin enhances brain activity in regions involved in sexual arousal and attraction. In men with HSDD, it increased penile response by up to 56% and improved happiness about sex. In women, it modulated brain areas involved in sexual and attraction processing [1][2].
Hypothalamic Amenorrhea Recovery
For women who've lost their periods due to stress, low body weight, or over-exercise, kisspeptin can help restart the reproductive system. It acts on the hypothalamus to reinitiate GnRH pulsing—the first step in bringing periods back naturally [5][12].
PT-141 (Bremelanotide)
Women with Low Sexual Desire (HSDD)
PT-141 is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder—when you used to have normal desire but it's faded, and it's causing real distress in your life. It's the only approved treatment that works through brain pathways rather than hormones.
Men Who Don't Respond to Viagra-Type Medications
While not FDA-approved for men, clinical research shows PT-141 may help men with erectile dysfunction who don't respond to PDE5 inhibitors like Viagra or Cialis. Because it works through the brain rather than blood vessels, it offers a completely different approach.
Those Wanting On-Demand Treatment
Unlike daily medications like flibanserin (Addyi), PT-141 is used only when you want it—take it 45 minutes before intimacy. This gives you control over timing without committing to daily pills.
People Seeking to Address the 'Wanting' Part of Intimacy
Many sexual health treatments focus on the physical mechanics (blood flow, lubrication). PT-141 is unique because it targets desire itself—the psychological 'wanting' that initiates intimacy. It works on your brain's arousal circuits.
Side effects
Kisspeptin-10
Common
- Flushing or warmth
- Injection site reactions
- Mild headache
Uncommon
- Temporary heart rate increase
- Dizziness
Serious
- Allergic reaction
PT-141 (Bremelanotide)
Common
- Nausea
- Facial flushing
- Headache
- Injection site reactions
Uncommon
- Skin darkening (hyperpigmentation)
Serious
- Blood pressure increase
Safety & evidence
Kisspeptin-10
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Kisspeptin has demonstrated an excellent safety profile across multiple clinical trials at Imperial College London and other research centers. Studies involving healthy volunteers and patients with reproductive disorders have shown no serious adverse events. [5][13] The most common effects—flushing and feeling warm—are related to its mechanism of action and resolve quickly. [15][20] Importantly, kisspeptin doesn't cause anxiety or negative psychological effects, which was confirmed in a study of 95 participants [4].
Contraindications
- Pregnancy or planning to become pregnant
- Hormone-sensitive cancers (breast, prostate, ovarian)
- Known allergy to peptide components
- Children and adolescents (unless under specialist care for delayed puberty)
PT-141 (Bremelanotide)
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
PT-141 has undergone rigorous FDA review and was approved in 2019 based on two large Phase 3 clinical trials involving over 1,200 women. The most common side effect is nausea (affecting about 40% of users), which typically decreases with repeated use. The drug causes transient increases in blood pressure (average 2-3 mmHg) and slight decreases in heart rate, which is why it's contraindicated in uncontrolled hypertension. Long-term safety data from the 52-week extension study showed no new safety concerns.
Contraindications
- Uncontrolled high blood pressure
- Cardiovascular disease
- History of heart attack or stroke
- Pregnancy or planning pregnancy
- Currently breastfeeding
Which is right for you?
Choose Kisspeptin-10 if...
- Fertility support and optimization
- Natural testosterone enhancement
- IVF treatment (oocyte maturation)
- Sexual health and libido improvement
Choose PT-141 (Bremelanotide) if...
- Restoring sexual desire
- Treating hypoactive sexual desire disorder (HSDD)
- Enhancing arousal response
- Supporting intimacy when desire is low